Table 2.
Chemotherapy exposures of participants
| Variable and Category | SJLIFE Participants, n=2753 | SJLIFE Nonparticipants, n=1668 | P Value | ||
|---|---|---|---|---|---|
| Frequency | Percentage | Frequency | Percentage | ||
| Nephrectomy | |||||
| No | 2549 | 92.6 | 1550 | 92.9 | 0.68 |
| Yes | 204 | 7.4 | 118 | 7.1 | |
| High-dose methotrexate | |||||
| No | 2006 | 72.9 | 1267 | 76.0 | 0.02 |
| Yes | 747 | 27.1 | 401 | 24.0 | |
| High-dose methotrexate, g/m2 | |||||
| Mean (SD) | 21.4 (28.7)a | 22.3 (28.9)b | 0.22c | ||
| Median (IQR) | 15.2 (4.1–21.7) | 15.2 (5.1–21.9) | |||
| Ifosfamide | |||||
| No | 2558 | 92.9 | 1576 | 94.5 | 0.04 |
| Yes | 195 | 7.1 | 92 | 5.5 | |
| Ifosfamide, g/m2 | |||||
| Mean (SD) | 42.5 (20.7)d | 36.9 (21.7)e | 0.002c | ||
| Median (IQR) | 41.1 (25.8–57.0) | 37.4 (18.0–48.6) | |||
| Cisplatin | |||||
| No | 2532 | 92.0 | 1545 | 92.6 | 0.43 |
| Yes | 221 | 8.0 | 123 | 7.4 | |
| Cisplatin, mg/m2 | |||||
| Mean (SD) | 402.9 (196.6)f | 441.9 (231.6)g | 0.93c | ||
| Median (IQR) | 397.6 (287.5–450.6) | 400.0 (300.0–531.4) | |||
| Carboplatin | |||||
| No | 2618 | 95.1 | 1574 | 94.4 | 0.29 |
| Yes | 135 | 4.9 | 94 | 5.6 | |
| Carboplatin, mg/m2 | |||||
| Mean (SD) | 3081.0 (2066.9)h | 3020.3 (1897.5)i | 0.35c | ||
| Median (IQR) | 2783.3 (1633.8–3789.3) | 2750.9 (1834.1–3664.6) | |||
| High-dose cyclophosphamide | |||||
| Missing | 14 | 0.5 | 52 | 3.1 | |
| No | 1805 | 65.6 | 1101 | 66.0 | 0.13 |
| Yes | 934 | 33.9 | 515 | 30.9 | |
Missing data are indicated.
a
Two patients.
b
Twenty-two patients.
c
t test.
d
One patient.
e
Four patients.
f
Eight patients.
g
Four patients.
h
Seven patients
i
Two patients.